Chi3L1 monoclonal antibodies for therapeutic and diagnostic use


Researchers at UTHealth describe studies aimed at elucidating the underlying cellular and molecular mechanisms of hepatic platelet accumulation during acute liver injurusing murine models of acetaminophen (APAP) -induced liver injury (AILI) and concanavalin A (Con A)-induced hepatitis. To take the researchers’ findings one step further toward the clinic, they generated mouse and human anti-CHI3L1 monoclonal antibodies. These data demonstrated the feasibility of targeting CHI3L1 by a neutralizing antibody to attenuate AILI. Together, these studies provided strong evidence for the potential of targeting CHI3L1 as a novel therapeutic strategy to improve the clinical outcomes of AILI and perhaps other acute liver injury conditions as well as potential to treat cancer.


UTHealth Ref. No.: 2020-0033

Inventors: Dr. Zhiqiang An, Dr. Ningyan Zhang, Dr. Cynthia Ju, et. al. 

Patent Status: PCT application filed PCT/US2021/028338

License Available: world-wide, exclusive or non-exclusive

Associated Publications: eLife 2021;10:e68571 DOI: 10.7554/eLife.68571

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
For Information, Contact:
Christine Flynn
Associate Director, Licensing and New Venture Development
University of Texas Health Science Center At Houston
Zhiqiang An
Changqing (Cynthia) Ju
Ningyan Zhang
© 2021. All Rights Reserved. Powered by Inteum